We explored the effects of modified β-glucan derivatives from Saccharomyces cerevisiae on lung cancer. The study revealed promising results for a sulfated derivative (SCGS), which showed strong anti-tumor and anti-metastatic properties.
In a mouse model, SCGS significantly inhibited lung metastasis, reducing tumor nodules by 86.7% and enhancing immune response. These findings suggest SCGS's potential not only as an effective treatment for metastasis but also for future cancer drug development.
Read More
Marine yeast shows anticancer potentialProduction and characterization of novel marine black yeast's exopolysaccharide with potential antiradical and anticancer prospects.
Promising anticancer treatment explored
We isolated a unique exopolysaccharide (EPS) from the marine black yeast Hortaea werneckii, which shows promising anti-cancer effects. This EPS demonstrated significant anticancer activity against A549 human lung cancer cells, with an IC50 of just 22.9 μg/mL, making it quite effective.
Remarkably, it showed minimal toxicity to normal lung cells, indicating its potential safety for further development. Additionally, the EPS also displayed strong antiradical properties. These findings suggest that H. werneckii could be a valuable resource in the fight against lung cancer.
Read More
New ginsenoside shows anti-cancer potentialProduction of a bioactive unnatural ginsenoside by metabolically engineered yeasts based on a new UDP-glycosyltransferase from Bacillus subtilis.
High relevance for cancer research
We investigated the production of a special ginsenoside, 3β,12β-Di-O-Glc-PPD, through engineered yeasts. This ginsenoside, derived from a new enzyme found in Bacillus subtilis, was shown to have notable anti-lung cancer effects.
While traditional methods for ginsenoside production are complex and costly, our approach offers a more efficient synthetic biology route. We found that this ginsenoside had better anti-cancer activity than one of the leading natural variants, promising a significant step forward in lung cancer treatment options.
Read More
Beta-glucan improves drug sensitivityYeast -glucan Increases Etoposide Sensitivity in Lung Cancer Cell Line A549 by Suppressing Nuclear Factor Erythroid 2-Related Factor 2 via the Noncanonical Nuclear Factor Kappa B Pathway.
Significant relevance to lung cancer.
We investigated how yeast-derived beta-glucan might improve the effectiveness of etoposide, a key chemotherapy drug for lung cancer. By using the A549 lung cancer cell line, we discovered that beta-glucan reduced levels of the protein Nrf2, which is often involved in drug resistance. This led to a heightened sensitivity to etoposide.
Additionally, our research highlighted the importance of specific signaling pathways in this process. However, the results suggest that while beta-glucan shows promise as a supportive treatment for overcoming drug resistance, it may not entirely replace conventional therapies.
Read More
We explored how squalene-type triterpenoids (STs) from Saccharomyces cerevisiae could impact non-small cell lung cancer (NSCLC) cells. Evaluating three compounds, we found that ST-3 was the most effective at inhibiting cancer cell growth. By optimizing a specific gene expression in our yeast, we significantly increased the amount of ST-3 produced. The final result was a remarkable yield of 78.61 mg/L after fermentation. This research not only highlights the potential of ST-3 but also sheds light on how we can enhance its production.
Read More